BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM $310M
1-Year Return
6.98%
This Quarter Return
-13.86%
1 Year Return
+6.98%
3 Year Return
+59.66%
5 Year Return
–
10 Year Return
–
AUM
$310M
AUM Growth
-$124M
(-29%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-6.92%
Top 10 Holdings %
Top 10 Hldgs %
68.81%
Holding
86
New
8
Increased
20
Reduced
4
Closed
13
Top Buys
| 1 |
ProShares UltraPro QQQ
TQQQ
|
+$10M |
| 2 |
Civeo
CVEO
|
+$8.01M |
| 3 |
Holley
HLLY
|
+$5.98M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$3.28M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$2.79M |
Top Sells
| 1 |
Klaviyo
KVYO
|
+$44.5M |
| 2 |
SLRN
ACELYRIN
SLRN
|
+$8.74M |
| 3 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
+$3.07M |
| 4 |
MREO
Mereo BioPharma
MREO
|
+$2.35M |
| 5 |
GoHealth
GOCO
|
+$1.61M |
Sector Composition
| 1 | Healthcare | 44.2% |
| 2 | Financials | 32.56% |
| 3 | Technology | 12.36% |
| 4 | Consumer Discretionary | 6.99% |
| 5 | Energy | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuveen Churchill Direct Lending
NCDL
$741M
| $68.6M | 22.12% |
4,039,553
| – | – |
|
2
Blue Owl Capital
OBDC
$7.04B
| $30M | 9.67% |
2,045,070
| – | – |
|
3
Cullinan Oncology
CGEM
$365M
| $18.4M | 5.95% |
2,435,972
+65,000
| +3% | +$492K |
|
4
EverCommerce
EVCM
$2.14B
| $16.6M | 5.34% |
1,641,929
| – | – |
|
5
Tourmaline Bio
TRML
$1.23B
| $15.8M | 5.09% |
1,037,107
-42,214
| -4% | -$642K |
|
6
Conduent
CNDT
$455M
| $15.4M | 4.96% |
5,697,450
+71,991
| +1% | +$194K |
|
7
enGene Holdings
ENGN
$315M
| $14.7M | 4.74% |
3,279,378
+119,403
| +4% | +$535K |
|
|
8
Holley
HLLY
$399M
| $13.7M | 4.41% |
5,318,040
+2,327,746
| +78% | +$5.98M |
|
9
Larimar Therapeutics
LRMR
$354M
| $10.3M | 3.31% |
4,778,040
+125,000
| +3% | +$269K |
|
|
10
ProShares UltraPro QQQ
TQQQ
$27.3B
| $10M | 3.23% |
+175,000
| New | +$10M |
|
|
11
Civeo
CVEO
$286M
| $8.01M | 2.58% |
+348,226
| New | +$8.01M |
|
12
Disc Medicine
IRON
$2.17B
| $6.96M | 2.25% |
140,260
+20,000
| +17% | +$993K |
|
13
Eledon Pharmaceuticals
ELDN
$141M
| $6.17M | 1.99% |
1,819,912
-140,000
| -7% | -$475K |
|
14
Compass Therapeutics
CMPX
$623M
| $5.61M | 1.81% |
2,954,712
| – | – |
|
15
Ultragenyx Pharmaceutical
RARE
$2.82B
| $5.55M | 1.79% |
153,238
+35,000
| +30% | +$1.27M |
|
|
IMA
16
ImageneBio, Inc. Common Stock
IMA
$94.8M
| $5.24M | 1.69% |
340,927
| – | – |
|
|
CNTA
17
Centessa Pharmaceuticals
CNTA
$2.96B
| $4.53M | 1.46% |
315,000
+95,000
| +43% | +$1.37M |
|
18
Context Therapeutics
CNTX
$77.6M
| $4.51M | 1.45% |
7,367,906
+1,009,978
| +16% | +$618K |
|
19
Sagimet Biosciences
SGMT
$204M
| $4.33M | 1.4% |
1,328,351
+4,474
| +0.3% | +$14.6K |
|
20
EyePoint Pharmaceuticals
EYPT
$953M
| $4.32M | 1.39% |
797,594
+130,000
| +19% | +$705K |
|
21
Pliant Therapeutics
PLRX
$92.7M
| $4.01M | 1.29% |
2,969,199
+200,000
| +7% | +$270K |
|
|
PVLA
22
Palvella Therapeutics, Inc. Common Stock
PVLA
$633M
| $3.93M | 1.27% |
140,259
-109,803
| -44% | -$3.07M |
|
23
Repare Therapeutics
RPTX
$75.2M
| $3.4M | 1.09% |
3,443,659
| – | – |
|
|
ETWO
24
DELISTED
E2open Parent Holdings
ETWO
| $3.3M | 1.06% |
1,650,943
| – | – |
|
|
25
Mineralys Therapeutics
MLYS
$2.97B
| $3.28M | 1.06% |
+206,296
| New | +$3.28M |
|